Alpelisib as an adjunctive treatment was studied in a phase II trial of 102 patients with previously treated advanced BRAF-mutant CRC treated with encorafenib plus cetuximab with or without alpelisib. The gene discussed is BRAF; the disease is colorectal carcinoma.